Search General Info
Search Education
Search Partnering Companies
Oxymo Technologies Inc.
2:45 PM - 3:00 PM (EDT), Monday, June 5, 2023 ・ Session Room 104B
![BIO International Convention](/sites/default/files/2021-09/_BIO_CONV_Logo-White.png)
Oxymo Technologies, a French-Canadian biotech, is developing Oximo, a topical drug product for the treatment of oral and genital herpes, a therapeutic indication characterized by a clear unmet medical need. Oxymo Technologies filled a Pre-IND Briefing Book in early February 2023 to ascertain that the pre-clinical data and intended Phase I/IIa design are adequate to proceed early clinical trials in human subjects. Feedback from the FDA is expected by mid-April 2023. Oxymo Technologies is looking for partners and investors to proceed to Phase I/IIa clinical trial to confirm Oximo efficacy and safety/tolerability in recurrent herpes labialis (RHL) patients. Infections caused by viruses of the herpes-virus family are increasingly frequent. One of the most common forms of such infections is RHL. According to the NIH, 50 to 80% of American adults have oral herpes. The WHO estimates that 67% of the world population are HSV1 infected and 13% HSV2 infected.
![](https://778c1607566f28c5e8fd-e6db6de54823ad7fd298e0f6ff75b72a.ssl.cf1.rackcdn.com/BIO_4121_EOISBJNL_681_OxymoTechnologiesInc-FileId-329869.png)
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Quebec
Company HQ Country:
Canada
Year Founded:
2015
Main Therapeutic Focus:
Infectious Diseases
Lead Product in Development:
Oximo, a topical drug product for the treatment of oral and genital herpes
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
![](https://www.conferenceharvester.com/uploads/harvester/photos/EOISBJNL-Presenter-HubertM.jpg)
BIO DOUBLE HELIX SPONSORS
![Sanofi logo](/sites/default/files/2022-05/Sanofi_Color_jpg_Double%20Helix.jpg)
![Eli Lilly and Company](/sites/default/files/2019-09/Eli%20Lilly%20and%20Company.png)
![Amgen logo](/sites/default/files/2022-05/Amgen_Color_png_Double%20Helix.png)
![Genentech logo](/sites/default/files/2022-05/Genentech_Color_png_Double%20Helix.png)
![Merck_logo_2022](/sites/default/files/2022-10/Merck_Color_.png)
![Avantor](/sites/default/files/2021-06/Avantor-BIO-DH-578.png)
![GSK logo](/sites/default/files/2023-04/gsk_color_png.png)
BIO HELIX SPONSORS
![Johnson and Johnson](/sites/default/files/2021-06/Johnson-Johnson-BIO-DH-578.png)
![Takeda logo](/sites/default/files/2022-05/Takeda_Color_jpg_Premier.jpg)
![Travere logo](/sites/default/files/2022-05/Travere_Color_png_Helix%20large.png)
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved